New antidiabetic drugs are being developed today that expand the range of 
pharmacological intervention, in particular for patients with type 2 diabetes 
(imeglimin, semaglutide, dulaglutide, FGF 21 analogue). At the same time 
innovations take place that "better" the well-proven molecules, they offer new 
application forms we have no experience of diabetology (osmotic pump for 
exenatide, faster acting insulin aspart). New properties are brought by just the 
change of concentration (insulin glargine in a concentration of 300 U/ml), 
unexpected positive results are also brought by new fixed-ratio combinations of 
antidiabetics (fixed-ratio combination of insulin degludec and liraglutide, 
fixed-ratio combination of insulin glargine and lixisenatide). Also results of 
clinical studies appear that concern molecules already in use which facilitate 
the formulation of new recommendations regarding treatment type 2 diabetes.Key 
words: type 2 diabetes mellitus - dulaglutide - FGF 21 - imeglimin - insulin 
aspart - insulin degludek - insulin glargine - ITCA 650 - liraglutide - national 
information diabetes system - semaglutide.